ProQR Therapeutics

PRQR

Market cap $236M

PRQR Hedge Fund Activity: Q1 2026 in Review

69 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q1 2026, worth a combined $56.8M — down 24% from $75.1M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new PRQR positions and 6 closed out — a net gain of 4 holders — while 14 added to existing stakes and 16 trimmed.

The largest buyer was Aberdeen Group, adding an estimated $600K. The largest seller was ArrowMark Colorado Holdings, exiting entirely with an estimated $2.35M sold.

• 69 institutional investors held ProQR Therapeutics (PRQR) as of Q1 2026, up from 65 in Q4 2025.
• Funds reported $56.8M of ProQR Therapeutics stock for Q1 2026, down 24% quarter-over-quarter.
• 10 funds opened new ProQR Therapeutics positions in Q1 2026 and 6 closed out, a net change of +4 holders.
• The largest ProQR Therapeutics buyer in Q1 2026 was Aberdeen Group, an estimated $600K added.
• The largest ProQR Therapeutics seller in Q1 2026 was ArrowMark Colorado Holdings, an estimated $2.35M sold.

Based on aggregated 13F filings for Q1 2026.